Dose-Proportionality and Intra-Individual Variability of Intracellular TFV-DP and FTC-TP in Healthy Volunteers
Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
Describe the dose-proportionality and intra-individual variability of tenofovir diphosphate
(TFV-DP) and emtricitabine triphosphate (FTC-TP) at steady-state in healthy human
participants taking Truvada® (FTC 200mg/TDF 300 mg) under direct observation.
Phase:
Phase 1
Details
Lead Sponsor:
HIV Prevention Trials Network
Treatments:
Emtricitabine Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Tenofovir